Currently Viewing:
COA 2017-ONCOLOGY PAYMENT REFORM
David Merrill and John Robinson Discuss Barriers to APMs, Factors of Interest
January 15, 2018
Dr Jeff Patton Discusses Preparing for OCM, Seeing Improved Outcomes and Savings
January 12, 2018
Currently Reading
Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models
January 11, 2018
Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM
January 09, 2018
Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care
January 07, 2018
Bo Gamble on COA's Role in 2018
January 05, 2018
Judy Berger on What Southwest Airlines Is Doing in Oncology
January 04, 2018
Terrill Jordan Discusses Making Refinements in Year 2 of OCM
January 03, 2018
Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate
December 26, 2017
Terrill Jordan: Year 1 Feedback on OCM
December 22, 2017
Dr Lucio Gordan: Improving Population Health Through Alternative Payment Models
December 08, 2017
Dr Ira Klein on Pharmaceutical Interest in Alternative Payment Models
December 07, 2017
Dr Ira Klein Outlines the Biggest Challenge of Value-Based Drug Pricing
November 05, 2017
Stakeholders Weigh-in on Payment Reform in Cancer Care
October 25, 2017
The Commercial Payer OCM Experience: Year 1
October 25, 2017
Terrill Jordan: Education and Data Are Key for OCM Success
October 25, 2017
Physicians Need Clearer Metrics Before Taking on 2-Sided Risk
October 25, 2017
Dr Jeff Patton Highlights Challenges Encountered With Implementing OCM
October 24, 2017
Dr Lucio Gordan: How Practices and Payers Work Together to Implement OCM
October 24, 2017

Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models

Involving providers in the development process of new reimbursement models increases the chance that the initiative will be successful and works against caregiver burnout, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma. 


Involving providers in the development process of new reimbursement models increases the chance that the initiative will be successful and works against caregiver burnout, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma. 

Transcript (slightly modified)

Should providers be involved in the development process of new reimbursement models?

I’m a crusader almost for the quadruple aim. Mostly everybody within healthcare, research, and healthcare policy understands the triple aim. The quadruple aim is additive to all the benefits of the triple aim. Quadruple aim, though, says exactly what your question implies: that we need to be including front-line caregivers when we’re designing these quality initiatives, whether it’s a CMS initiative, whether it’s a hospital initiative, or if you have a progressive group. If it’s an office-based quality improvement initiative, it’ll work umpteen times better if you include the front-line caregivers as early as you can in the design phase.

So, we’re doing that in Oklahoma. The 5 oncology practices that are part of OCM, we have brought together and we’re trying to make our own collaborative design for patients under 65 in Oklahoma, so we’ll see if it works. But, that’s precisely what we should be doing. Including the caregivers early on does 2 things: it increases the chance that the initiative will be successful, and it works against caregiver burnout, whether it’s a nurse or a doctor, pharmacist, or administrator, or lay caregivers who take care of our patients at home. We are all subject to burnout, and having caregivers as part of the design team lowers that risk.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!